ULB Research ⤶ |
Description of the Unit | Projects of the Unit | Composition |
Collaborations of the Unit | Protected technologies | Publications | Skills |
Faculty of Medicine | Bordet Institute
Interfaculty institutes | U-CRC: ULB Cancer Research Center
(Code: ULB305)
Télévie - Entreprises privées.
The project investigates new machanisms to overcome MAPK pathway inhibitors in BRAF or NRAS mutated melanomas.
Région wallonne - Organisations internationales - Entreprises privées.
The gene expression level of Tyrp1 in melanoma metadteses correlates with patients' survival. The evaluation of this gene and its corresponding protein ...
Organisations internationales - Autres ressources extérieures.
Evaluation of the cytotoxic effect and molecular mechanisms associated with the sensitivity to the tyrosine kinase inhibitor dasatinib in a panel of me ...
Autres fonds publics belges - Entreprises privées.
Kinase profiling in melanoma metatstatic tissue allows to obtain a precise image of the global activity of signaling pathways and to correlate it with ...
Autres fonds publics belges - Entreprises privées.
It is evident that cell culture is an essential research tool. However, it is important that it represents the tissue of origine at best as well as the ...
Télévie - Entreprises étrangères - Autres ressources extérieures.
The development of a complementary kinome/mutation screening tool that will aid in the investigation of possible treatments for patients with melanoma.